title: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
abstract: Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III. IDH2 encoding mitochondrial NADP+-dependent isocitrate dehydrogenase is also mutated in these tumors, albeit at much lower frequencies. Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors. To determine mutation types and their frequencies, we examined 1,010 diffuse gliomas. We detected 716 IDH1 mutations and 31 IDH2 mutations. We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III. We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities. IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors. In addition, patients with anaplastic glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
authors: Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 220/221, Heidelberg, Germany.
authors: Christian
authors: C
authors: Hartmann
authors: Jochen
authors: J
authors: Meyer
authors: Jörg
authors: J
authors: Balss
authors: David
authors: D
authors: Capper
authors: Wolf
authors: W
authors: Mueller
authors: Arne
authors: A
authors: Christians
authors: Jörg
authors: J
authors: Felsberg
authors: Marietta
authors: M
authors: Wolter
authors: Christian
authors: C
authors: Mawrin
authors: Wolfgang
authors: W
authors: Wick
authors: Michael
authors: M
authors: Weller
authors: Christel
authors: C
authors: Herold-Mende
authors: Andreas
authors: A
authors: Unterberg
authors: Judith W M
authors: JW
authors: Jeuken
authors: Peter
authors: P
authors: Wesseling
authors: Guido
authors: G
authors: Reifenberger
authors: Andreas
authors: A
authors: von Deimling
mesh_terms: D000328:Adult; D000367:Age Factors; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D002454:Cell Differentiation; D004252:DNA Mutational Analysis; D005260:Female; D005910:Glioma / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D014407:Tumor Cells, Cultured
chemical_list: D007521:Isocitrate Dehydrogenase